Publications

2024

Ren Z, Vanhooren J, Derpoorter C, De Moerloose B and Lammens T. (2024). A 69 Long Non-Coding RNA Signature Predicts Relapse and Acts as Independent Prognostic Factor in Pediatric AML. Blood Advances. in press. DOI: 10.1182/bloodadvances.2024012667. PMID: 38640434.

    2023

    De Coninck S, De Smedt R, Lintermans B, Reunes L, Kosasih HJ, Reekmans A, Brown LM, Van Roy N, Palhais B, Roels J, Van der Linden M, Van Dorpe J, Ntziachristos P, van Delft FW, Mansour MR, Pieters T, Lammens T, De Moerloose B, de Bock CE, Goossens S and Van Vlierberghe P. (2023). Targeting hyperactive platelet-derived growth factor receptor-β signaling in T-cell acute lymphoblastic leukemia and lymphoma. Haematologica, 109 (5): 1373- 13784. DOI: 10.3324/haematol.2023.283981. PMID: 37941480

    Vanhooren J*, Dobbelaere R*, Derpoorter C*, Deneweth L*, Van Camp L, Uyttebroeck A, De Moerloose B and Lammens T. (2023). CAR-T in the treatment of acute myeloid leukemia: barriers and how to overcome them. Hemasphere 7 (9): e937. DOI: 10.1097/HS9.0000000000000937. (* These authors contributed equally). PMID: 37674860

    Förster A, Davenport C, Duployez N, Erlacher M, Ferster A, Fitzgibbon J, Göhring G, Hasle H, Jongmans MC, Kolenova A, Kronnie G, Lammens T, Mecucci C, Mlynarski W, Niemeyer CM, Sole F, Szczepanski T, Waanders E, Biondi A, Wlodarski M, Schlegelberger B and Ripperger T. (2023). European standard clinical practice – Key issues for the medical care of individuals with familial leukemia. Eur J Med Genet. 66(4): 104727. Doi: 10.1016/j.ejmg.2023.104727. PMID: 36775010

    Van Trimpont M, Schalk AM, De Visser Y, Nguyen HA, Reunes L, Vandemeulebroecke K, Peeters E, Su Y, Lee H, Lorenzi PL, Chan WK, Mondelaers V, De Moerloose B, Lammens T, Goossens S, Van Vlierberghe P and Lavie A. (2023). In vivo stabilization of a less toxic asparaginase variant leads to a durable anti-tumor response in acute Leukemia. Haematologica 108 (2): 409–419. DOI:10.3324/haematol.2022.281390. PMID: 35979719

    2022

    De Vos N, Hofmans M, Lammens T, De Wilde B, Van Roy N and De Moerloose B. (2022). Targeted therapy in juvenile myelomonocytic leukemia: Where are we now? Ped. Blood Cancer 69 (11): e29930. DOI: 10.1002/pbc29930. PMID: 36094370

    Derpoorter C, Van Paemel R, Vandemeulebroecke K, Vanhooren J, De Wilde B, Laureys G and Lammens T. (2022). Whole genome sequencing and inheritance-based variant filtering as a tool for unraveling missing heritability in pediatric cancer. Pediatric Hematol. Oncol. 40 (4): 326-340. DOI: 10.1080/08880018.2022.2101723. PMID: 35876323

    Feenstra LR, R. Gehring R, van Geijswijk IM, König T, Prinsen HCMT, Vandemeulebroecke K, Lammens T, Krupa A, and Teske E. (2022). Evaluation of PEG-L-Asparaginase in asparagine suppression and anti-drug antibody development in healthy beagle dogs: A multi-phase preclinical study. The Vet J. 286: 105854. DOI: 10.1016/j.tvjl.2022.105854. PMID: 35781075

    Luijts T, Elliott K, Siaw JT, Van de Velde J, Beyls E, Claeys A, Lammens T, Larsson E, Willaert W, Vral A and Van den Eynden J. (2022). A clinically annotated post-mortem approach to study multi-organ somatic mutational clonality in normal tissues. Sci. Rep. 12: 10322. DOI: 10.1038/s41598-022-14240-8. PMID: 35725896

    Vanhooren J, Van Camp L, Depreter B, de Jong M, Uyttebroeck A, Van Damme A, Dedeken L, Dress MF, van der Werff ten Bosch J, Hofmans M, Philippé J, De Moerloose B and Lammens T. (2022). Deciphering the non-coding landscape of pediatric acute myeloid leukemia. Cancers 14: 2098. DOI: 10.3390/cancers14092098  PMID: 35565228

    Diez-Fraile A, De Ceulaer J, Derpoorter C, Spaas C, De Backer T, Lamoral P, Abeloos J and Lammens T. (2022). Tracking the molecular fingerprint of head and neck cancer for recurrence detection in liquid biopsis. Int. J. Mol. Sci. 23: 2403. DOI: 10.3390/ijms23052403. PMID: 35269544

    Van Trimpont M, Peeters E, De Visser Y, Schalk AM, Mondelaers V, De Moerloose B, Lavie A, Lammens T, Goossens S, and Van Vlierberghe P. (2022). Novel insights on the use of L-Asparaginase as an efficient and safe anti-cancer therapy. Cancers 14 (4): 902. DOI: 10.3390/cancers14040902. PMID: 35205650

    Van Paemel R, Vandeputte C, Raman L, Van Thorre J, Willems L, Van Dorpe J, Van Der Linden M, De Wilde J, De Koker A, Menten B, Vicha A, Schleiermacher G, Iddir Y, Chicard M, van Zogchel L, Stutterheim J, Lak N, Tytgat GAM, Speleman F, De Wilde B, Lammens T*, De Preter K* and Van Roy N*. (2022). The feasibility of using liquid biopsies as a complementary assay for copy number aberration profiling in routinely collected pediatric cancer patient samples. Eur J Cancer 160: 12-23. DOI: 10.1016/j.ejca.2021.09.022 (* These authors contributed equally). PMID: 34794856

    2021

    Boer JM, Valsecchi MG, Hormann FM, Antić Ž, Zaliova M, Schwab C, Cazzaniga G, Arfeuille C, Cavé H, Attarbaschi A, Strehl S, Escherich G, Imamura T, Ohki K, Grüber TA, Sutton R, Pastorczak A, Lammens T, Lambert F, Li CK, Carrillo de Santa Pau E, Hoffmann S, Möricke A, Harrison CJ, Den Boer ML, De Lorenzo P, Stam RW, Bergmann AK and Pieters R. (2021). Favorable outcome of NUTM1-rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia in a collaborative international study. Leukemia 35(10): 2978-2982. DOI: 10.1038/s41375-021-01333-y. PMID: 34211097

    Decker M, Lammens T, Ferster A, Erlacher M, Yoshimi A, Niemeyer CM, Ernst MPT, Raaijmakers MHGP, Duployez N, Flaum A, Steinemann D, Schlegelberger B, Illig T, Ripperger T. (2021). Functional classification of RUNX1 variants in familial platelet disorder with associated myeloid malignancies. Leukemia. Epub ahead of print. DOI: 10.1038/s41375-021-01200-w. PMID: 33692461

    Vanhooren J, Derpoorter C, Depreter B, Deneweth L, Philippé J, De Moerloose B and Lammens T. (2021). TARP as antigen in cancer immunotherapy. Cancer Immunol. Immunother. 70 (11): 3061 – 3068. DOI: 10.1007/s00262-021-02972-x. PMID: 34050774

    Matthijssens F, Sharma ND, Nysus M, Nickl CK, Kang H, Perez DR, Lintermans B, Van Loocke W, Roels J, Peirs S, Demoen L, Pieters T, Reunes L, Lammens T, De Moerloose B, Van Nieuwerburgh F, Deforce DL, Cheung LC, Kotecha RS, Risseeuw MDP, Van Calenbergh S, Takarada T, Yoneda Y, van Delft FW, Lock RB, Merkley SD, Chigaev A, Sklar LA, Mullighan CG, Loh ML, Winter SS, Hunger SP, Goossens S, Castillo EF, Ornatowski W, Van Vlierberghe P and Matlawska-Wasowska K. (2021). RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia. J. Clin. Invest. 131 (6): e141566. DOI: 10.1172/JCI141566. PMID: 335555272

    Hofmans M, Lammens T, Depreter B, Wu Y, Erlacher M, Caye A, Cavé H, Flotho C, de Haas V, Niemeyer CM, Stary J, Van Nieuwerburgh F, Deforce D, Van Loocke W, Van Vlierberghe P, Philippé J and De Moerloose B. (2021). Long non-coding RNAs as novel therapeutic targets in juvenile myelomonocytic leukemia. Sci Rep. 11 (1): 2801. DOI: 10.1038/s41598-021-82509-5. PMID: 33531590

    Diez-Fraile A, Ceulaer J, Derpoorter C, Spaas C, Backer T, Lamoral P, Abeloos J and Lammens T. (2021). Circulating Non-Coding RNAs in head and neck cancer: Roles in diagnosis, prognosis, and therapy monitoring. Cells 10 (1): 48. DOI: 10.3390/cells10010048. PMID: 33396240

    Dal Molin A, Hofmans M, Gaffo E, Buratin A, Cavé H, Flotho C, de Haas V, Niemeyer CM, Stary J, Van Vlierberghe P, Philippé J, De Moerloose B, te Kronnie G, Bresolin S, Lammens T* and Bortoluzzi S*. (2021). CircRNAs dysregulated in juvenile myelomonocytic leukemia: CircMCTP1 stands out. Front. Cell Dev. Biol. 8: 613540. DOI: 10.3389/fcell.2020.613540. PMID: 33490078

    2020

    Roels J, Thénoz M, Szarzyńska B, Landfors M, De Coninck S, Demoen L, Provez L, Kuchmiy A, Strubbe S, Reunes L, Pieters T, Matthijssens F, Van Loocke W, Erarslan-Uysal B, Richter-Pechańska P, Declerck K, Lammens T, De Moerloose B, Deforce D, Van Nieuwerburgh F, Cheung LC, Kotecha RS, Mansour MR, Ghesquière B, Van Camp G, Berghe WV, Kowalczyk JR, Szczepański T, Davé UP, Kulozik AE, Goossens S, Curtis DJ, Taghon T, Dawidowska M, Degerman S and Van Vlierberghe P. (2020). Aging of preleukemic thymocytes drives CpG island hypermethylation in T-cell acute lymphoblastic leukemia. Blood Canc. Discov. 1 (3): 274  – 289. DOI: 10.1158/2643-3230.bcd-20-0059. PMID: 33179015

    Depreter B, De Moerloose B, Vandepoele K, Uyttebroeck A, Van Damme A, Terras E, Denys B, Dedeken L, Dresse MF, Van der Werff Ten Bosch J, Hofmans M, Philippé J and Lammens T (2020).Deciphering molecular heterogeneity in pediatric AML using a cancer vs. normal transcriptomic approach. Pediatr. Res. 89 (7): 1695 – 1705. 2020. DOI: 10.1038/s41390-020-01199-3. PMID: 33069162

    Zubovic L, Piazza S, Tebaldi T, Cozzuto L, Palazzo G, Sidarovich V, De Sanctis V, Bertorelli R, Lammens T, Hofmans M, De Moerloose B, Ponomarenko J, Pigazzi M, Masetti R, Mecucci C, Basso G and Macchi P. (2020). The altered transcriptome of pediatric myelodysplastic syndrome revealed by RNA sequencing. J. Hematol. Oncol. 13 (1): 135.  DOI: 10.1186/s13045-020-00974-3. PMID: 33046098

    Carmichael CL, Wang J, Nguyen T, Kolawole O, Benyoucef A, De Mazière C, Milne AR, Samuel S, Gillinder K, Hediyeh-zadeh S, Vo ANQ, Huang Y, Knezevic K, McInnes WRL, Shields BJ, Mitchell H, Ritchie ME, Lammens T, Lintermans B, Van Vlierberghe P, Wong NC, Haigh K, Thoms JAI, Toulmin E, Curtis DJ, Oxley EP, Dickins RA, Beck D, Perkins A, McCormack MP, Davis MJ, Berx G, Zuber J, Pimanda JE, Kile BT, Goossens S and Haigh JJ. (2020). The EMT modulator SNAI1 contributes to AML pathogenesis via its interaction with LSD1. Blood 136 (8): 957-973. DOI: 10.1182/blood.2019002548. PMID: 32369597

    Van Paemel R, De Koker A, Vandeputte C, van Zogchel L, Lammens T, Laureys G, Vandesompele J, Schleiermacher G, Chicard M, Van Roy N, Vicha A, Tytgat GAM, Callewaert N, De Preter K and De Wilde B. (2020). Minimally invasive classification of paediatric solid tumours using reduced representation bisulphite sequencing of cell-free DNA: a proof-of-principle study.  Epigenetics 16 (2): 196-208. DOI: 10.1080/15592294.2020. PMID: 32662719

    Van Paemel R, Vlug R, De Preter K, Van Roy N, Speleman F, Willems L, Lammens T, Laureys G, Schleiermacher G, Tytgat GAM, Astrahantseff K, Deubzer H and De Wilde B. (2020). Correction to: The pitfalls and promise of liquid biopsies for diagnosing and treating solid tumors in children : a review. Eur. J. Pediatr. 179 (9): 1497 – 1498. DOI: 10.1007/s00431-020-03692-7. PMID: 31897843

    De Smedt R, Morscio J, Reunes L, Roels J, Bardelli V, Lintermans B, Van Loocke W, Almeida A, Cheung LC, Kotecha RS, Mansour MR, Uyttebroeck A, Vandenberghe P, La Starza R, Mecucci C, Lammens T, Van Roy N, De Moerloose B, Barata JT, Taghon T, Goossens S, Van Vlierberghe P. (2020). Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma. Blood 135 (19): 1685–1695. DOI: 10.1182/blood.2019003880. PMID: 34440292

    Depreter B, Weening K, Vandepoele K, Essand M, De Moerloose B, Themeli M, Cloos J, Hanekamp D, Moors I, D’hont I, Denys B, Uyttebroeck A, Van Damme A, Dedeken L, Snauwaert S, Goetgeluk G, De Munter S, Kerre T, Vandekerckhove B, Lammens T* and Philippé J*. (2020). TARP is an immunotherapeutic target in acute myeloid leukemia expressed in the leukemic stem cell compartment. Haematologica 105(5): 1306-1316. DOI: 10.3324/haematol.2019.222612. (* Both authors contributed equally). PMID: 31371409

    Depreter B, De Moerloose B, Vandepoele K, Uyttebroeck A, Van Damme A, Denys B, Dedeken, L,  Dresse MF, Van der Werff Ten Bosch J, Hofmans M, Kerre T, Vandekerckhove B, Philippé J and Lammens  T. (2020). Clinical significance of TARP expression in pediatric acute myeloid leukemia. Hemasphere 4 (2): e346. DOI: 10.1097/HS9.0000000000000346. PMID: 32309783 

    Van Lierde E, Goubert L, Lammens T, Ben Brahim L, Van den Bussche E and Vervoort T. (2020). The interplay of parent and child coping responses in understanding child functioning in the context of living with a parent with or without chronic pain. Clin. J. Pain 36 (4): 238-248. DOI: 10.1097/AJP.0000000000000801. PMID: 31977374

    Mondelaers V, Ferster A, Uyttebroeck A, Brichard B, der Werff ten Bosch J, Norga K, Francotte N, Piette C, Vandemeulebroecke K, Verbeke C, Schmidt S, Benoit Y, Lammens L* and De Moerloose B*. (2020). Prospective, real-time monitoring of pegylated Escherichia coli and Erwinia asparaginase therapy in childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma in Belgium. Brit. J. Haematol. 190 (1): 105-114. DOI: 10.1111/bjh.16495. PMID: 32057100 

    Van Paemel R, Vlug R, De Preter K, Van Roy N, Speleman F, Willems L, Lammens T, Laureys G, Schleiermacher G, Tytgat GAM, Astrahantseff K, Deubzer H and De Wilde B. (2020). The pitfalls and promise of liquid biopsies for diagnosing and treating solid tumors in children : a review. Eur. J. Pediatr. 179 (2): 191 – 202. DOI: 10.1007/s00431-019-03545-y. PMID: 31897843

    Hofmans M, Schroeder R, Lammens T, Flotho C, Niemeyer C, Van Roy N, Decaluwe W, Philippé J and De Moerloose B. (2020). Noonan syndrome-associated myeloproliferative disorder with somatically acquired monosomy 7 : impact on clinical decision making. Brit. J. Haematol. 187(4): e83-e86. DOI: 10.1111/bjh.16191. PMID: 31617209

    2019

    Pieters T, T’Sas S, Demoen L, Almeida A, Haenebalcke L, Matthijssens F, Lemeire K, D’Hont J, Van Rockeghem F, Hochepied T, Lintermans B, Reunes L, Lammens T, Berx G, Haigh JJ, Goossens S and Van Vlierberghe P (2019). Novel strategy for rapid functional in vivo validation of oncogenic drivers in haematological malignancies. Sci. Rep. 9: 10577. DOI: 10.1038/s41598-019-46853-x. PMID: 34406363

    De Moerloose B, Reedijk A, de Bock GH, Lammens T, de Haas V, Denys B, Dedeken L, van den Heuvel-Eibrink MM, te Loo M, Uyttebroeck A, Van Damme A, Van der Werff-ten Bosch J, Zsiros J, Kaspers G and de Bont E. (2019). Response-guided chemotherapy for pediatric acute myeloid leukemia without hematopoietic stem cell transplantation in first complete remission: Results from protocol DB AML-01. Pediatr. Blood Cancer 66: e27605. DOI: 10.1002/pbc.27605. PMD: 30623572

    Milani G, Matthijssens F, Van Loocke W, Durinck K, Roels J, Peirs S, Thénoz M, Pieters T, Reunes L, Lintermans B, Vandamme N, Lammens T, Van Roy N, Van Nieuwerburgh F, Deforce D, Schwab C, Raimondi S, Dalla Pozza L, Carroll III AJ, De Moerloose B, Benoit Y, Goossens S, Berx G, Harrison CJ, Basso G, Cavé H, Sutton R, Asnafi V, Meijerink J, Mullighan C, Loh M and Van Vlierberghe P. (2019). Genetic characterization and therapeutic targeting of MYC‐rearranged T cell acute lymphoblastic leukaemia. Br J Haematol, 185: 169-174. DOI:10.1111/bjh.15425. PMID: 29938777

    Derpoorter C, Vandepoele K, Diez Fraile A, Vandemeulebroecke K, De Wilde B, Speleman F, Van Roy N, Lammens T and Laureys G. (2019). Pinpointing a potential role for CLEC12B in cancer predisposition through familial exome sequencing. Pediatr. Blood Cancer 66: e27513. DOI: 10.1002/pbc.27513. PMID: 30350915

    De Smedt R, Peirs S, Morscio J, Matthijssens F, Roels J, Reunes L, Lintermans B, Goossens S, Lammens T, Van Roy N, Touzart A, Jenni S, Tsai YC, Lovisa F, Mussolin L, Serafin V, Van Nieuwerburgh F, Deforce D, Uyttebroeck A, Tousseyn T, Burkhardt B, Klapper W, De Moerloose B, Benoit Y, Macintyre E, Bourquin JP, Basso G, Accordi B, Bornhauser B, Meijerink J, Vandenberghe P and Van Vlierberghe P. (2019). Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma. Haematologica 104 (1): e17 – e20. DOI: 10.3324/haematol.2018.199257. PMID: 30076176

    2018

    Bomken S, van der Werff Ten Bosch J, Attarbaschi A, Bacon CM, Borkhardt A, Boztug K, Fischer U, Hauck F, Kuiper RP, Lammens T, Loeffen J, Neven B, Pan-Hammarström Q, Quinti I, Seidel MG, Warnatz K, Wehr C, Lankester AC, Gennery AR (2018). Current understanding and future research priorities in malignancy associated with inborn errors of immunity and DNA repair disorders : the perspective of an interdisciplinary working group. Front. Immunol. 9: 2912. DOI: 10.3389/fimmu.2018.02912. PMID: 30619276

    Alexander TB, Gu Z, Iacobucci I, Dickerson K, Choi JK, Xu B, Payne-Turner D, Yoshihara H, Loh ML, Horan J, Buldini B, Basso G, Elitzur S, de Haas V, Zwaan CM, Yeoh A, Reinhardt D, Tomizawa D, Kiyokawa N, Lammens T, De Moerloose B, Catchpoole D, Hori H, Moorman A, Moore AS, Hrusak O, Meshinchi S, Orgel E, Devidas M, Borowitz M, Wood B, Heerema NA, Carrol A, Yang YL, Smith MA, Davidsen TM, Hermida LC, Gesuwan P, Marra MA, Ma Y, Mungall AJ, Moore RA, Jones SJM, Valentine M, Janke LJ, Rubnitz JE, Pui CH, Ding L, Liu Y, Zhang J, Nichols KE, Downing JR, Cao X, Shi L, Pounds S, Newman S, Pei D, Guidry Auvil JM, Gerhard DS, Hunger SP, Inaba H and Mullighan CG. (2018). The genetic basis and cell of origin of mixed phenotype acute leukaemia. Nature 562 (7727): 373–379. DOI: 10.1038/s41586-018-0436-0. PMID: 30209392

    Zeka F, Decock A, Van Goethem A, Vanderheyden K, Demuynck F, Lammens T, Helsmoortel HH, Vermeulen J, Noguera R, Berbegall AP, Combaret V, Schleiermacher G, Laureys G, Schramm A, Schulte JH, Rahmann S, Bienertová-Vašků J, Mazánek P, Jeison M, Ash S, Hogarty MD, Moreno-Smith M, Barbieri E, Shohet J, Berthold F, Van Maerken T, Speleman F, Fischer M, De Preter K, Mestdagh P and Vandesompele J. (2018). Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients. JCI Insight. 3 (23): e97021. DOI: 10.1172/jci.insight.97021. PMID: 33404859

    Hanekamp D., Denys B., Kaspers GJL, te Marvelde JG, Schuurhuis GJ, De Haas V, De Moerloose B, de Bont ES, Zwaan CM, de Jong A, Depreter B, Lammens T, Philippé J, Cloos J and van der Velden V.H.J. (2018). Leukaemic stem cell load at diagnosis predicts the development of relapse in young acute myeloid leukaemia patients. Brit. J. Haematol. 183(3): 512–516. DOI: 10.1111/bjh.14991. PMID: 29076143

    Derpoorter C, Bordon Cueto De Braem M, Laureys G, Haerynck F and Lammens T. (2018). Genes at the crossroad of primary immunodeficiencies and cancer. Front. Immunol. 9: e2544. DOI: 10.3389/fimmu.2018.02544. PMID: 30443258

    Hofmans M, Lammens T, Helsmoortel H, Bresolin S, Cavé H, Flotho C, Hasle H, van den Heuvel-Eibrink MM, Niemeyer C, Stary J, Van Roy N, Van Vlierberghe P, Philippé J and De Moerloose B. (2018). The long non-coding RNA landscape in juvenile myelomonocytic leukemia. Haematologica 103 (11): e501–e504. DOI: 10.3324/haematol.2018.189977. PMID: 29858388

    Corrias MV, Parodi S, Tchirkov A, Lammens T, Vicha A, Pasqualini C, Träger C, Yáñez Y, Dallorso S, Varesio L, Luksch R, Laureys G, Valteau-Couanet D, Canete A, Pöetschger U, Ladenstein R and Burchill SA (2018). Event-free survival of infants and toddlers enrolled in the HR-NBL-1/SIOPEN trial is associated with the level of neuroblastoma mRNAs at diagnosis. Pediatr. Blood Cancer 65: e27052. DOI: 10.1002/pbc.27052. PMID: 29603574

    Depreter B, Philippé J, Meul M, Denys B, Vandepoele K, De Moerloose B and Lammens T. (2018). Cancer-related mRNA expression analysis using a novel flow cytometry-based assay. Cytom. Part B-Clin. Cytom. 94 (4): 565–575. DOI: 10.1002/cyto.b.21593. PMID: 28980766

    Obenauer JC, Kavelaars FG, Sanders MA, de Vries AC, de Haas V, Beverloo HB, De Moerloose B, Lammens T, Dworzak M, Hoogenboezem RM, Valk PJM, Touw IP and van den Heuvel‐Eibrink MM. (2018). Recurrently affected genes in juvenile myelomonocytic leukaemia. Brit. J. Haematol. 182 (1): 135–138. DOI: 10.1111/bjh.14737. PMID: 28485469

    Nguyen HA, Su Y, Zhang JY, Antanasijevic A, Caffrey M, Schalk AM, Liu L, Rondelli D, Oh A, Mahmud DL, Bosland MC, Kajdacsy-Balla A, Peirs S, Lammens T, Mondelaers V, De Moerloose B, Goossens S, Schlicht MJJ, Kabirov KK, Lyubimov AV, Merrill BJ, Saunthararajah Y, Van Vlierberghe P and Lavie A. (2018). A novel L-asparaginase with low L-glutaminase coactivity is highly efficacious against both T- and B-cell acute lymphoblastic leukemias in vivo. Cancer Res. 78 (6): 1549 – 1560. DOI: 10.1158/0008-5472.CAN-17-2106. PMID: 29343523

    2017

    Van Roy N, Van Der Linden M, Menten B, Dheedene A, Vandeputte C, Van Dorpe J, Laureys G, Renard M, Sante T, Lammens T, De Wilde B, Speleman F and De Preter K. (2017). Shallow whole genome sequencing on circulating cell-free DNA allows reliable noninvasive copy-number profiling in neuroblastoma patients. Clin. Cancer Res. 23 (20): 6305 – 6314. DOI: 10.1158/1078-0432.CCR-17-0675. PMID: 28710315

    Benard-Slagter A, Zondervan I, de Groot K, Ghazavi F, Sarhadi V, Van Vlierberghe P, De Moerloose B, Schwab C, Vettenranta K, Harrison CJ, Knuutila S, Schouten J, Lammens T and Savola S. (2017). Digital multiplex ligation-dependent probe amplification for detection of key copy number alterations in T- and B-cell lymphoblastic leukemia. J. Mol. Diagn. 19 (5): 659–672. DOI: 10.1016/j.jmoldx.2017.05.004. PMID: 28736295

    Lammens T, Durinck K, Wallaert A, Speleman F, and Van Vlierberghe P. (2017). Long non-coding RNAs in leukemia : biology and clinical impact. Curr. Opin. Hematol. 24 (4): 353-358. DOI: 10.1097/MOH.0000000000000354. PMID: 28441150

    2016

    Ghazavi F, De Moerloose B, Van Loocke W, Wallaert A, Helsmoortel H, Ferster A, Bakkus M, Plat G, Delabesse E, Uyttebroeck A, Van Nieuwerburgh F, Deforce D, Van Roy N, Speleman F, Benoit Y, Lammens T and Van Vlierberghe P. (2016). Unique long non-coding RNA expression signature in ETV6/RUNX1-driven B-cell precursor acute lymphoblastic leukemia. Oncotarget 7 (45): 73769–73780. DOI: 10.18632/oncotarget.12063. PMID: 27650541